<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622462</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-STR-PPOEL-1</org_study_id>
    <nct_id>NCT04622462</nct_id>
  </id_info>
  <brief_title>Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment</brief_title>
  <official_title>A Multi-Centre Prospective Community-Based Observational Study on Prediction of Malignant Progression of Clinically Suspicious Oral Lesions With STRATICYTE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proteocyte Diagnostics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proteocyte Diagnostics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to evaluate the utility of the S100A7&#xD;
      immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of&#xD;
      progression to cancer of clinically suspicious oral lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The standard of care for potentially premalignant oral epithelial lesion (PPOEL)&#xD;
      risk assessment for progression to cancer is dysplasia grading by histopathology. With&#xD;
      significant overlap between dysplasia grades and high inter- and intra-observer variations,&#xD;
      dysplasia grading alone has been shown to be inadequate as a prognostic tool. To investigate&#xD;
      the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in&#xD;
      the early diagnosis of invasive oral cancer, a prospective multi-center observational study&#xD;
      was designed with specimens obtained from community-based practices.&#xD;
&#xD;
      Methods: Patients that qualify to enroll in the study will be assessed for both standard of&#xD;
      care histopathological assessment for dysplasia grade and STRATICYTE risk assessment, and&#xD;
      followed for up to 60 months (from initial biopsy) to determine the outcome of their oral&#xD;
      lesion(s).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Malignant Transformation Rate: Dysplasia</measure>
    <time_frame>60 months</time_frame>
    <description>Cancer progression rate in patients with oral neoplasia with dysplasia and STRATICYTE Low-Risk or Elevated Risk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malignant Transformation Rate: No Dysplasia</measure>
    <time_frame>60 months</time_frame>
    <description>Cancer progression rate in patients with oral neoplasia without dysplasia and STRATICYTE Low-Risk or Elevated-Risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Rate</measure>
    <time_frame>60 months</time_frame>
    <description>Recurrence rate in patients with oral neoplasia with or without dysplasia and STRATICYTE Low-Risk or Elevated-Risk</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Oral Neoplasm</condition>
  <arm_group>
    <arm_group_label>Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia</arm_group_label>
    <description>No evidence of dysplasia&#xD;
Mild dysplasia&#xD;
Moderate dysplasia&#xD;
Severe dysplasia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care Histopathology</intervention_name>
    <description>Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer</description>
    <arm_group_label>Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia</arm_group_label>
    <other_name>H&amp;E assessment for dysplasia grade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>STRATICYTE Assessment</intervention_name>
    <description>Assessment for risk of progression to oral cancer</description>
    <arm_group_label>Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia</arm_group_label>
    <other_name>S100A7 Immunohistochemistry Signature-based Assessment</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin-fixed paraffin-embedded tissue sections stained with H&amp;E and S100A7&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be selected from community-based Oral &amp; Maxillofacial Surgery&#xD;
        practices in the provinces of Ontario and Alberta, Canada&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral&#xD;
             squamous cell carcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Biopsied lesion with or without dysplasia concomitant with oral squamous cell&#xD;
             carcinoma at initial biopsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Darling, MSc, MChD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Hwang, PhD</last_name>
    <phone>(647) 255-1370</phone>
    <email>jhwang@proteocyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Darling, MSc, MChD</last_name>
    <phone>(519) 661-2111</phone>
    <phone_ext>86399</phone_ext>
    <email>mark.darling@schulich.uwo.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kingsway Oral &amp; Maxillofacial Surgery</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim McGaw, DDS, MSc, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tim McGaw, DDS, MSc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim McGaw, DDS, MSc, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tim McGaw, DDS, MSc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western University</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Darling, MSc, MChD</last_name>
    </contact>
    <investigator>
      <last_name>Mark Darling, MSc, MChD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Hwang JT, Gu YR, Shen M, Ralhan R, Walfish PG, Pritzker KP, Mock D. Individualized five-year risk assessment for oral premalignant lesion progression to cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Mar;123(3):374-381. doi: 10.1016/j.oooo.2016.11.004. Epub 2016 Nov 22.</citation>
    <PMID>28110942</PMID>
  </reference>
  <reference>
    <citation>Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, Macmillan C, Siu KW, Walfish PG, Ralhan R. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Int J Cancer. 2014 Mar 15;134(6):1379-88. doi: 10.1002/ijc.28473. Epub 2013 Oct 8.</citation>
    <PMID>24122701</PMID>
  </reference>
  <reference>
    <citation>Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R, Siu KW. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One. 2010 Aug 3;5(8):e11939. doi: 10.1371/journal.pone.0011939.</citation>
    <PMID>20689826</PMID>
  </reference>
  <reference>
    <citation>Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res. 2009 Jan;8(1):300-9. doi: 10.1021/pr800501j.</citation>
    <PMID>19072117</PMID>
  </reference>
  <reference>
    <citation>Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Datta Gupta S, Bahadur S, Siu KW. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 2008 Jun;7(6):1162-73. doi: 10.1074/mcp.M700500-MCP200. Epub 2008 Mar 13.</citation>
    <PMID>18339795</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukoplakia</keyword>
  <keyword>Erythroplakia</keyword>
  <keyword>Erythroleukoplakia</keyword>
  <keyword>Lesion</keyword>
  <keyword>Oral Epithelial Dysplasia</keyword>
  <keyword>S100A7 Biomarker</keyword>
  <keyword>S100A7 Immunohistochemistry Signature-based</keyword>
  <keyword>Early Diagnosis</keyword>
  <keyword>STRATICYTE</keyword>
  <keyword>Oral Neoplasia</keyword>
  <keyword>Oral Epithelial Atypia</keyword>
  <keyword>Hyperplasia</keyword>
  <keyword>Hyperkeratosis</keyword>
  <keyword>Oral Squamous Cell Carcinoma</keyword>
  <keyword>Oral Cancer</keyword>
  <keyword>Potentially Premalignant Oral Epithelial Lesion</keyword>
  <keyword>OPMD</keyword>
  <keyword>Mild Dysplasia</keyword>
  <keyword>Moderate Dysplasia</keyword>
  <keyword>Severe Dysplasia</keyword>
  <keyword>Low-grade Dysplasia</keyword>
  <keyword>High-grade Dysplasia</keyword>
  <keyword>Personalized Medicine</keyword>
  <keyword>Predictive Assay</keyword>
  <keyword>Whole Slide Imaging</keyword>
  <keyword>Computational Pathology</keyword>
  <keyword>Digital Pathology</keyword>
  <keyword>Artificial Intelligence</keyword>
  <keyword>Machine Learning</keyword>
  <keyword>OPML</keyword>
  <keyword>Oral Potentially Malignant Disorder</keyword>
  <keyword>Oral Potentially Malignant Lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

